Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 5/20 | 0.69 |
| ▸ | CSF1R | P07333 | 12/20 | 0.60 |
| ▸ | PDGFRB | P09619 | 7/20 | 0.60 |
| ▸ | FLT4 | P35916 | 7/20 | 0.60 |
| ▸ | FLT3 | P36888 | 5/20 | 0.60 |
| ▸ | RAF1 | P04049 | 1/20 | 0.59 |
| ▸ | KIT | P10721 | 1/20 | 0.59 |
| ▸ | FLT1 | P17948 | 1/20 | 0.59 |
| ▸ | BRAF | P15056 | 1/20 | 0.56 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.56 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1108413 | 0.85 | KMT2A (0.55) | KDRCSF1RPDGFRBFLT4FLT3 | |
| SCHEMBL4288514 | 0.81 | KDR (1.00) | KDRCSF1RPDGFRBFLT4FLT3 | |
| SCHEMBL9370053 | 0.78 | EPHX2 (0.71) | KDRRAB9A | |
| SCHEMBL13937021 | 0.78 | CSF1R (0.62) | KDRCSF1RPDGFRBFLT4FLT3 | |
| SCHEMBL4293211 | 0.77 | KDR (0.92) | KDRCSF1RPDGFRBFLT4FLT3 | |
| SCHEMBL1098249 | 0.75 | PDGFRB (1.00) | KDRCSF1RPDGFRBFLT4FLT3 | |
| SCHEMBL3979754 | 0.75 | EGFR (0.69) | KDRCSF1RPDGFRBFLT4RAF1 | |
| SCHEMBL13528798 | 0.75 | EPHX2 (0.61) | KDRBRAFRAB9A | |
| SCHEMBL30715572 | 0.75 | SRC (0.61) | KDRPDGFRBFLT4FLT3KIT | |
| SCHEMBL20731086 | 0.74 | KDR (0.59) | KDRCSF1RPDGFRBFLT4RAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153643-B2 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2012-04-10 | — | — | US | disclosed |
| US-20090233924-A1 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233924-A1 | Quinazoline derivatives | AQP1, PGF, F12 | KDR 27/4885CSF1R 362/4885PDGFRB 700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.